Kamelian T, et al. – In 2016, researchers designed a double–blind, randomized clinical trial on 119 vitamin D deficient patients. As evidence accumulates, they propose that in these patients 1,25(OH)2D3 has a positive association with serum FGF23, and hypostasized that serum calcium might be a down regulator of serum FGF23.

Methods

• Researchers carried out a double-blind, randomized clinical trial on 119 vitamin D deficient patients in 2016.
• They examined biochemical variables of treatment and placebo groups after 12 weeks of 50,000 IU of Cholecalciferol vs. placebo therapy once a week, by SPSS18.

Results

• Evidence showed that delta of serum PTH in treatment group was less than the controls (P < 0.001) after Cholecalciferol therapy.
• Nevertheless, it was showed that delta values of serum 25(OH)D3, 1,25(OH)2D3 and FGF23 in vitamin D treated group were more than the placebo-treated ones (P < 0.001, P = 0.002, and P = 0.04, respectively).
• Furthermore, FGF23 serum level in treatment group was associated with serum calcium (P = 0.005, r = -0.256), and serum 1,25(OH)2D3 (P < 0.001, r = 0.529).